Table I.

HLA-A2-reactivity of T lymphocytes generated with gp100-transduced DCsa

IFN-γ (pg/ml)
MediaT2 pulsed with PeptidesTumors
Patient A
DC-gp10047102 1654 1384 2170 340 700 6345
Patient B
DC-gp100<16<16 464 499 1629 250 384 <16<16
  • a gp100-transduced DCs were used to stimulate autologous T cells prepared from melanoma patients. Patient A: T cells received one stimulation with DCs, and the recognition assay was performed 14 days later. Patient B: autologous T cells received two stimulations with DCs 14 days apart, and the recognition assay was performed 28 days after the first stimulation. Specificity of stimulated T cells from both patients was analyzed using T2 cells pulsed with the influenza M-1 peptide (fluM1) or with the gp100-specific peptides gp100154–162 (G9-154), gp100209–217 (G9-209), or gp100280–288 (G9-280). Also, HLA-A2+/gp100+ tumor cells (624.38 and SK23) or HLA-A2/gp100+ (586) or HLA-A2+/gp100 (MDA231) tumor cells were used as targets. Results are expressed in picograms per milliliter of IFN-γ released following a 24-h coculture. DC-gp100, gp100-transduced DCs. DC-control, DCs transduced with the parental retroviral vector.